We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
- Authors
Morizane, Chigusa; Okusaka, Takuji; Ueno, Hideki; Kondo, Shunsuke; Ikeda, Masafumi; Furuse, Junji; Shinichi, Ohkawa; Nakachi, Kohei; Mitsunaga, Shuichi; Kojima, Yasushi; Suzuki, Eiichiro; Ueno, Makoto; Yamaguchi, Tomohiro
- Abstract
There is no standard regimen for gemcitabine (Gem)-refractory pancreatic cancer (PC) patients. In a previous phase II trial, S-1 was found to exhibit marginal efficacy. Gem administration by fixed dose rate infusion of 10 mg/m(2)/min (FDR-Gem) should maximize the rate of intracellular accumulation of gemcitabine triphosphate and might improve clinical efficacy. We conducted the phase I/II of FDR-Gem and S-1 (FGS) in patients with Gem-refractory PC.
- Publication
Cancer chemotherapy and pharmacology, 2012, Vol 69, Issue 4, p957
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-011-1786-6